The IPOX® Watch: BoneSupport Holding AB (BONEX SS)
COMPANY DESCRIPTION
Founded in 1999, BONESUPPORT Holding AB is a commercial stage orthobiologics company headquartered in Lund, Sweden. BoneSupport develops and commercializes injectable and drug-eluting bio-ceramic synthetic bone graft substitutes for the treatments of fractures, bone infection, and bone voids by remodeling to patient's host bone and stimulating bone healing.
BUSINESS MODEL
BoneSupport generates revenue through the sale of three commercial products CERAMENT® BVF (BONE VOID FILLER) and the antibiotics-containing CERAMENT® G and CERAMENT® V through both direct sales and distributors.
IPO HISTORY
On 06/21/2017, BoneSupport Holding began trading on Nasdaq Stockholm's main market led by ABG Sundal Collier. The orthobiologics company offered 17,241,379 new shares at SEK 29.00 per share, mid-point of its expected price range (SEK 27 to SEK 31). BoneSupport was valued at ca. SEK 1.416 million at offer with the 15% over-allotment option fully exercised. The shares opened at SEK 30.90 and closed the first day higher at SEK 32.00 (+10.34%).
BoneSupport Holding AB was included in the IPOX® 100 Europe Index (ETF: FPXE US, FPXE LN, EFPX IM) on 03/21/2022 and has gained +160.77% since addition to the indexes.
